Drug Type Peptide drug conjugates |
Synonyms + [5] |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain Cancer | Phase 1 | Canada | 15 Apr 2010 | |
Neoplasms | Preclinical | Canada | 30 Jan 2022 | |
Diabetes Mellitus, Type 2 | Discovery | Canada | 30 Jan 2022 | |
Obesity | Discovery | Canada | 30 Jan 2022 |